Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Metastatic Medullary Thyroid Carcinoma
NCT00390325Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2006
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in medullary thyroid carcinoma (MTC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Nov 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT00390325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390325.